How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

466 results for

Pulmonary Hypertension in Sickle Cell Anemia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Pulmonary capillary hemangiomatosis: an uncommon cause of pulmonary hypertension (PubMed)

Gláucia G Marchiori Edson E eng por Letter Comment Brazil J Bras Pneumol 101222274 1806-3713 0 Phosphodiesterase 5 Inhibitors 0 Piperazines 0 Sulfones IM J Bras Pneumol. 2011 Mar-Apr;37(2):272-6 21537664 J Bras Pneumol. 2012 Jan-Feb;38(1):143-4 22407053 Anemia, Sickle Cell complications Female Humans Hypertension, Pulmonary drug therapy etiology Phosphodiesterase 5 Inhibitors therapeutic use Piperazines therapeutic use Schistosomiasis complications Sulfones therapeutic use 2013 7 17 6 0 2013 7 17 6 0 (...) Pulmonary capillary hemangiomatosis: an uncommon cause of pulmonary hypertension 23857691 2014 05 07 2018 12 02 1806-3756 39 3 2013 May-Jun Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia J Bras Pneumol Pulmonary capillary hemangiomatosis: an uncommon cause of pulmonary hypertension. 390-2 10.1590/S1806-37132013000300019 S1806-37132013000300390 Faria Igor Murad IM Carneiro Leonardo Hoehl LH Tiradentes Teófilo Augusto Araújo TA Zanetti

Full Text available with Trip Pro

2013 Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia

102. Hemoglobin sickle cell disease in Brazil (PubMed)

Hemoglobin sickle cell disease in Brazil 23277594 2014 04 14 2018 12 02 1592-8721 98 1 2013 Jan Haematologica Haematologica Hemoglobin sickle cell disease in Brazil. e9 10.3324/haematol.2012.076828 Cabañas-Pedro Ana Carolina AC Braga Josefina A P JA Camilo-Araújo Roberta F RF Silva Ana I M AI Vicari Perla P Figueiredo Maria M eng Letter Comment Italy Haematologica 0417435 0390-6078 IM Haematologica. 2012 Aug;97(8):1136-41 22315500 Anemia, Sickle Cell complications Female Humans Hypertension (...) , Pulmonary etiology Kidney Diseases etiology Male 2013 1 2 6 0 2013 1 2 6 0 2014 4 15 6 0 ppublish 23277594 haematol.2012.076828 10.3324/haematol.2012.076828 PMC3533669 Hum Hered. 1983;33(2):125-9 6862455 Lancet. 2000 Jul 8;356(9224):168-9 10963278 Hemoglobin. 2001 Aug;25(3):297-303 11570722 Clin Lab Haematol. 2004 Feb;26(1):15-9 14738432 Haematologica. 2012 Aug;97(8):1136-41 22315500 Hum Hered. 1994 Nov-Dec;44(6):322-7 7860085 Am J Hematol. 1996 Oct;53(2):72-6 8892730 Cad Saude Publica. 2005 Jul-Aug;21

Full Text available with Trip Pro

2013 Haematologica

103. Study of SANGUINATEâ„¢ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

for Study: 19 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients with Homozygous (HbSS) Sickle Cell Anemia; Hb levels: >6g/dL - <10g/dL; Age : >18 years old; Frequency of ER hospitalizations < 6x/yr for SCD pain events documented "medical history". Exclusion Criteria: Patients, who are on chronic transfusion program, defined as regular transfusions every 2-8 weeks; Allergic to Hydroxyurea; History of clinical (...) Responsible Party: Prolong Pharmaceuticals ClinicalTrials.gov Identifier: Other Study ID Numbers: SGSC-003 First Posted: May 8, 2013 Last Update Posted: December 3, 2014 Last Verified: December 2014 Keywords provided by Prolong Pharmaceuticals: SANGUINATE Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Hydroxyurea Antineoplastic Agents Antisickling Agents

2013 Clinical Trials

104. Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

Inclusion Criteria: Sickle cell disease, including sickle cell anemia (SS), sickle-hemoglobin C disease (SC), and sickle beta thalassemia disease (Sb). Ongoing opioid analgesic therapy for chronic sickle cell disease-associated pain. Subjects must be on a stable dose of analgesic medication (opioid or other) for at least 2 weeks before enrollment. All men and women in this study must agree to use adequate birth control during this study. Acceptable barrier birth control methods are a male condom, female (...) : Other Study ID Numbers: U54HL117664-01 6610 ( Other Identifier: UCSF Clinical and Translational Science Institute ) First Posted: January 18, 2013 Last Update Posted: May 2, 2018 Last Verified: April 2018 Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn

2013 Clinical Trials

105. Is Resistance Futile?. Hemodynamics in Sickle Cell Disease (PubMed)

, Sickle Cell complications Female Humans Hypertension, Pulmonary etiology Male 2013 4 17 6 0 2013 4 17 6 0 2013 6 12 6 0 ppublish 23586378 10.1164/rccm.201303-0410ED PMC3707370 Haematologica. 2013 Mar;98(3):464-72 22983573 Eur Respir J. 2012 Jan;39(1):112-8 21778170 Am J Respir Crit Care Med. 2013 Apr 15;187(8):840-7 23348978 Blood. 2003 Feb 15;101(4):1257-61 12393669 N Engl J Med. 2004 Feb 26;350(9):886-95 14985486 Liver Transpl. 2005 Sep;11(9):1107-11 16123953 Br J Haematol. 2006 Jul;134(1):109-15 (...) Is Resistance Futile?. Hemodynamics in Sickle Cell Disease 23586378 2013 06 11 2018 12 02 1535-4970 187 8 2013 Apr 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Is resistance futile?: Hemodynamics in sickle cell disease. 790-2 10.1164/rccm.201303-0410ED Smith Kerri Akaya KA Kawut Steven M SM eng Editorial Comment United States Am J Respir Crit Care Med 9421642 1073-449X AIM IM Am J Respir Crit Care Med. 2013 Apr 15;187(8):840-7 23348978 Anemia

Full Text available with Trip Pro

2013 American Journal of Respiratory and Critical Care Medicine

106. Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

with untreated moderate or severe obstructive sleep apnea (AHI>15) Patients with any coagulopathy Patients requiring nitrate therapy for any clinical indication Patients with an active prescription for pulmonary vasodilator medication other than oxygen Patients with a history of nonarteritic anterior ischemic optic neuropathy Contraindication to tadalafil use including allergy to: any PDE-5 inhibitor anatomical deformations of the penis sickle cell anemia multiple myeloma leukemia bleeding disorders active (...) Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tadalafil for Pulmonary

2013 Clinical Trials

107. Hydroxyurea in Pulmonary Arterial Hypertension

of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ) Study Details Study Description Go to Brief Summary: Pulmonary arterial hypertension (PAH) is a serious and eventually fatal disease damaging the lungs and the heart. It results from narrowing and eventual blockage of small blood vessels in the lung, due to abnormal proliferation of cells in the blood vessel (arterial). Patients with PAH suffer from fatigue, shortness of breath, low oxygen levels, blood clots and heart (...) marrow and blood of PAH patients causes the lung blood vessel disease. The drug hydroxyurea is used to inhibit the abnormally high level of bone marrow cell proliferation in patients with MPDs. It has been shown to reduce the numbers of circulating immature bone marrow cells in patients with MPDs. Hydroxyurea has been available for almost fifty years, and has been used to treat patients with MPDs, sickle cell anemia, and congenital heart disease for very prolonged periods of time, up to twenty

2013 Clinical Trials

108. A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

as 3 or more severe pain events per year in the 2 years prior to enrollment despite adequate supportive care measures and hydroxyurea trial (i.e. Hydroxyurea non-responders). Pain may occur in typical sites associated with vaso-occlusive painful events and cannot be explained by causes other than vaso-occlusion mediated by sickle cell disease. Recurrent priapism. Osteo-necrosis of multiple joints Evidence of Pulmonary Hypertension as evidenced by Tricuspid Regurgitation jet velocity (TRV) > 2.5 m/s (...) Study ID Numbers: 09-00383 First Posted: January 19, 2011 Results First Posted: April 3, 2019 Last Update Posted: April 3, 2019 Last Verified: April 2019 Keywords provided by Nationwide Children's Hospital: sickle cell stem cell transplant Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Cyclophosphamide Tacrolimus Busulfan Thymoglobulin Fludarabine

2011 Clinical Trials

109. Cardiovascular abnormalities in sickle cell disease. (PubMed)

Cardiovascular abnormalities in sickle cell disease. Sickle cell disease is characterized by recurrent episodes of ischemia-reperfusion injury to multiple vital organ systems and a chronic hemolytic anemia, both contributing to progressive organ dysfunction. The introduction of treatments that induce protective fetal hemoglobin and reduce infectious complications has greatly prolonged survival. However, with increased longevity, cardiovascular complications are increasingly evident (...) dysfunction. Chronic anemia in sickle cell disease results in cardiac chamber dilation and a compensatory increase in left ventricular mass. This is often accompanied by left ventricular diastolic dysfunction that has also been a strong independent predictor of mortality in patients with sickle cell disease. Both PH and diastolic dysfunction are associated with marked abnormalities in exercise capacity in these patients. Sudden death is an increasingly recognized problem, and further cardiac

Full Text available with Trip Pro

2012 Journal of the American College of Cardiology

110. Effects of HQK-1001 in Patients With Sickle Cell Disease

Study Description Go to Brief Summary: The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease. Condition or disease Intervention/treatment Phase Sickle Cell Disease Sickle Cell Anemia Sickle Cell Disorders Hemoglobin S Disease Sickling Disorder Due to Hemoglobin S Drug: HQK-1001 Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 77 participants Allocation (...) Cell Sickle Cell Trait Pathologic Processes Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn

2012 Clinical Trials

111. Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease

) ( National Heart, Lung, and Blood Institute (NHLBI) ): Sickle Cell Anemia Tyrosine Kinase Inhibitor Platelet Derived Growth Factor Beta Adrenergic Receptor Blocker Pulmonary Vascular Disease Sickle Cell Disease Pulmonary Hypertension Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Hypertension, Pulmonary Anemia, Sickle Cell Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases (...) Heart, Lung, and Blood Institute (NHLBI) Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ) Study Details Study Description Go to Brief Summary: Background: - About one-tenth of adults with sickle cell disease have pulmonary hypertension (high blood pressure in the lungs). This condition can cause shortness of breath, pain crisis, and congestive heart failure. It may even lead to death. Researchers

2012 Clinical Trials

112. Vascular Function Intervention Trial in Sickle Cell Disease

School of Hygiene and Tropical Medicine: Vascular function Ready to use supplementary foods Chloroquine Children Growth Nitric Oxide Additional relevant MeSH terms: Layout table for MeSH terms Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Chloroquine Chloroquine diphosphate Amebicides Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Antimalarials Antirheumatic Agents Anti-Inflammatory Agents (...) Vascular Function Intervention Trial in Sickle Cell Disease Vascular Function Intervention Trial in Sickle Cell Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Vascular Function Intervention Trial

2012 Clinical Trials

113. Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

Nephropathy Drug: Atorvastatin Drug: Placebo Phase 2 Detailed Description: It is well recognized that sickle cell disease (SCD) is characterized by a vasculopathy, with involvement of multiple organs including the brain, lung, spleen, and kidney. This results in multiple clinical complications, including ischemic stroke, pulmonary hypertension, autosplenectomy, as well as albuminuria and chronic renal disease. Several recent studies have confirmed the association of both albuminuria and renal dysfunction (...) the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 60 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Sickle cell anemia (HbSS) or Sickle-beta0 thalassemia (HbS-beta0thal) between ages of 18 and 60; albuminuria (micro- or macroalbuminuria, defined as =/> 30mg/g creatinine); serum alanine aminotransferase (ALT)

2012 Clinical Trials

114. Carbon Monoxide Levels and Sickle Cell Disease Severity

, and race with the sickle cell disease group. Design: Participants will be screened with a medical history. Participants with sickle cell disease will provide a blood sample and have a heart function test. They will also breathe into a bag to provide an exhaled breath sample. Healthy volunteers will provide an exhaled breath sample. No treatment or care will be provided as part of this study. Condition or disease Sickle Cell Disease Sickle Cell Anemia Anemia, Sickle Cell Detailed Description: Sickle (...) date Currently smoking Subjects with any known form of sickle cell disease (sickle trait will NOT be excluded) Subjects with any other known forms of hemolytic anemia Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01547793 Locations Layout table

2012 Clinical Trials

115. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. (PubMed)

High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Pulmonary hypertension is associated with reduced nitric oxide bioavailability and early mortality in sickle cell disease (SCD). We previously demonstrated that placenta growth factor (PlGF), an angiogenic factor produced by erythroid cells, induces hypoxia-independent expression of the pulmonary vasoconstrictor endothelin-1 in pulmonary endothelial cells. Using a lentivirus vector, we simulated (...) erythroid expression of PlGF in normal mice up to the levels seen in sickle mice. Consequently, endothelin-1 production increased, right ventricle pressures increased, and right ventricle hypertrophy and pulmonary changes occurred in the mice within 8 weeks. These findings were corroborated in 123 patients with SCD, in whom plasma PlGF levels were significantly associated with anemia, endothelin-1, and tricuspid regurgitant velocity; the latter is reflective of peak pulmonary artery pressure

Full Text available with Trip Pro

2010 Blood

116. FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis

. Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event (eg, deep venous thrombosis or pulmonary embolism) within 52 weeks prior to Day 1. Uncontrolled hypertension in the opinion of the investigator (eg, that requires change in anti-hypertensive medication within 2 weeks prior to randomization). Diagnosis or suspicion (eg, complex kidney cyst of Bosniak Category II or higher) of renal cell carcinoma as shown on screening renal ultrasound. History of malignancy except (...) the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, or in situ cancer at any site. Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (eg, systemic lupus erythematosis [SLE], rheumatoid arthritis, celiac disease). Clinically significant gastrointestinal bleeding. Known history of myelodysplastic syndrome, multiple myeloma, hereditary hematologic disease such as thalassemia, sickle

2015 Clinical Trials

117. FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

erythropoiesis (eg, systemic lupus erythematosis [SLE], rheumatoid arthritis, celiac disease). Clinically significant gastrointestinal bleeding. Known history of myelodysplastic syndrome, multiple myeloma, hereditary hematologic disease such as thalassemia, sickle cell anemia, pure red cell aplasia, or other known causes for anemia other than CKD, hemosiderosis, hemochromatosis, known coagulation disorder, or hypercoagulable condition. Any prior functioning organ transplant or a scheduled organ (...) . Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab). Chronic liver disease. New York Heart Association Class III or IV congestive heart failure. Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event (eg, deep venous thrombosis or pulmonary embolism) within 52 weeks prior to Day 1. Uncontrolled hypertension in the opinion of the investigator (eg, that requires

2015 Clinical Trials

118. Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

at visit 1; Hypotension (systolic blood pressure [SBP] < 100 mm Hg or diastolic blood pressure [DBP] < 50 mm Hg) (symptomatic orthostatic hypotension) at visit 1; Uncontrolled systemic hypertension (SBP > 180 mmHg; or DBP > 100 mmHg) at visit 1; Known penile deformities or conditions (e.g., sickle cell anemia, multiple myeloma, leukemia) that may predispose to priapism; Retinitis pigmentosa; History of vision loss; History of nonarteritic ischemic optic neuropathy; Veno-occlusive disease; History (...) Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2016 Clinical Trials

119. Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series) (PubMed)

aldosterone. Collectively, these mechanisms contribute to a contractile or hypertrophic pulmonary vascular phenotype. Genetically inherited disorders in hemoglobin structure are also an important etiology of abnormal pulmonary vasoreactivity. In sickle cell anemia, for example, consumption of the vasodilator and antimitogenic molecule nitric oxide by cell-free hemoglobin is an important mechanism underpinning pulmonary hypertension. Contemporary genomic and transcriptomic analytic methods have also (...) allowed for the discovery of novel risk factors relevant to sickle cell disease, including GALNT13 gene variants. In this report, we review cutting-edge observations characterizing these and other pathobiological mechanisms that contribute to pulmonary vascular and right ventricular vulnerability.

Full Text available with Trip Pro

2016 Pulmonary circulation

120. A Study of HQK-1001 in Patients With Sickle Cell Disease

, subject is able and willing to comply with necessary study procedures Exclusion Criteria: More than 4 hospitalizations for acute sickle cell related events in the previous 12 months prior to screening Pulmonary hypertension requiring oxygen therapy QTc > 450 msec (male) or 470 msec (female) on screening ECG (QT corrected by Fridericia's formula) Assigned to a regular transfusion program Use of erythropoiesis stimulating agents within 90 days of screening ALT > 3x upper limit of normal (ULN) Serum (...) Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease. Condition or disease Intervention/treatment Phase Sickle Cell Disease Sickle Cell Anemia Sickle Cell Disorders Hemoglobin S Disease Sickling Disorder Due to Hemoglobin S Drug: HQK-1001 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>